Brisou, G., Belot, A., Bachy, E., Ghesquieres, H., Gros, F., Bouabdallah, K., Cartron, G., Blasi, R. D., Houot, R., Rossi, C., Durand, A., Bras, F. L., Haioun, C., Gastinne, T., Dulery, R., Bories, P., Jardin, F., Guffroy, B., Fornecker, L., Castilla-Llorente, C., Damaj, G., Morschhauser, F., Loschi, M., Guidez, S., Sylvain, C., Schmidt, A., Rochelle, L. D. L., Rubio, M., Carras, S., Bay, J., Chauchet, A., Joris, M., Fouillet, L., Lebras, L., Abraham, J., Bijou, F., Hermine, O., Bonnet, A., Decroocq, J., Amorim, S., Morineau, N., Lionne, P., Dennetiere, S., Herbreteau, L., Drenou, B., Vincent, L., Olivier, G., Labouré, G., Fitoussi, O., Fruchart, C., Leyronnas, C., Cherblanc, F., Gat, E., Tessoulin, B. (2025). Comparison of axicabtagene ciloleucel to standard regimens as second line treatment for large B cell lymphoma in real life: A lysa study from descar-T and realysa registries. Blood. https://doi.org/10.1182/blood-2025-2764